Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Sangamo Therapeutics, Inc

OTC: SGMOQ · Life Sciences · 3 alerts · CIK 1001233

Share price
$0.1200Close, Nov 13
Market cap
$49.7M
Shares outstanding
414.27MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Sangamo Therapeutics, Inc filings on SEC EDGAR ↗

4:01 PM ET 8-K
Business Update

Sangamo Therapeutics Business Update

Sangamo Therapeutics filed amended monthly operating reports (MORs) for July and August 2026, along with a new MOR for September 2026, as part of its ongoing Chapter 11 bankruptcy proceedings. The reports provide updated cash balances, receipts, and disbursements required by the Bankruptcy Court but are not prepared in accordance with GAAP. The company's common stock was recently delisted from Nasdaq and currently trades on the OTC Expert Market.

6:00 AM ET 8-K
Bankruptcy & Restructuring

Sangamo Therapeutics Bankruptcy & Restructuring

Sangamo Therapeutics, Inc. filed a monthly operating report (MOR) for August 2026 as part of its ongoing Chapter 11 bankruptcy proceedings in the District of Delaware. The report discloses a month-end cash balance of $23.2 million and total liabilities of $107.3 million. Additionally, the company's common stock is being delisted from Nasdaq effective October 17, 2026, following its suspension in May 2026.

4:01 PM ET 8-K
Bankruptcy & Restructuring

Sangamo Therapeutics Bankruptcy & Restructuring

Sangamo Therapeutics completed the sale of its ST-920 (Fabry disease gene therapy) assets to PTC Therapeutics for $111 million in cash plus up to $100 million in contingent milestones. The sale was conducted via a court-supervised auction process as part of Sangamo's ongoing Chapter 11 bankruptcy proceedings. Additionally, the company's common stock is being formally delisted from Nasdaq effective September 27, 2026.

Counterparty
PTC Therapeutics, Inc.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.